Eversense news for Germany, Italy, Netherlands, Poland, Spain, and Switzerland. Click here to learn more

Patient Case Studies

Meet Gerry - 65 year old Athlete

Diagnosed 10 years ago with Type 1 diabetes, 65-yearold “Gerry” is an avid runner and former Medtronic CGM user. She disliked the sensor self-insertion process, and didn’t trust the accuracy of her readings, especially in the hypoglycemic range.

Learn More

Meet Tre - 24 year old

A 24-year-old Type 1 patient who was diagnosed 12 years ago, Tre works in his family’s business where he has an erratic schedule. Tre was not able to maintain consistent CGM use because of repeated issues with self-insertion and sensors falling out, and he didn’t always trust the results.

Learn More

Meet Maria - 45 year old

Maria is a 45-year-old Type 1 diabetes patient who was diagnosed at age 23. While she’s always known the importance of having a good A1c, her pursuit of that goal was sometimes at the expense of her overall glucose control, resulting in some hypoglycemic events that required treatment.

Learn More

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.